Zosano Pharma logo

ZSAN - Zosano Pharma Share Price

$1.44 -0.1  -5.3%

Last Trade - 13/12/19

Sector
Healthcare
Size
Micro Cap
Market Cap £21.1m
Enterprise Value £23.6m
Revenue £n/a
Position in Universe 5001st / 6391
Bullish
Bearish
Unlock ZSAN Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

ZSAN Revenue Unlock ZSAN Revenue

Net Income

ZSAN Net Income Unlock ZSAN Revenue

Normalised EPS

ZSAN Normalised EPS Unlock ZSAN Revenue

PE Ratio Range

ZSAN PE Ratio Range Unlock ZSAN Revenue

Dividend Yield Range

ZSAN Dividend Yield Range Unlock ZSAN Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2019
31st Dec 2020
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ZSAN EPS Forecasts Unlock ZSAN Revenue
Profile Summary

Zosano Pharma Corporation is a clinical-stage biopharmaceutical company. The Company is focused on providing systemic administration of therapeutics to patients using its Adhesive Dermally-Applied Microarray (ADAM) technology. ADAM is an intracutaneous delivery system designed to offer drug absorption into the bloodstream. ADAM consists of an array of drug-coated titanium microneedles mounted on an adhesive backing that is pressed on to the skin using a reusable handheld applicator. The Company’s Qtrypta (M207) is a formulation of zolmitriptan delivered utilizing its ADAM technology. Qtrypta (M207) is being investigated as a treatment to provide relief of migraine symptoms in the migraine cycle. The Company has developed its transdermal delivery system to administer novel formulations of existing drugs through the skin for the treatment of a variety of indications.

Directors
Last Annual December 31st, 2018
Last Interim September 30th, 2019
Incorporated January 26, 2012
Public Since January 27, 2015
No. of Shareholders: 9
No. of Employees: 53
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Capital Market
Shares in Issue 18,230,803
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ZSAN Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for ZSAN
Upcoming Events for ZSAN
Thursday 12th March, 2020 Estimate
Q4 2019 Zosano Pharma Corp Earnings Release
Tuesday 12th May, 2020 Estimate
Q1 2020 Zosano Pharma Corp Earnings Release
Similar to ZSAN
© Stockopedia 2019, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.